AMSTERDAM, December 4 /PRNewswire/ -- Biopharmaceutical company Kiadis
Pharma announces today that it has successfully completed treatment of the
last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor
lymphocyte cell based product, is under development to prevent acute Graft
versus Host Disease (GvHD) and allow early immune reconstitution following a
mismatched bone marrow transplantation. Nineteen end stage blood cancer
patients were treated with no cases of grade III/IV acute GvHD occurring
within the first 100 days after ATIR(TM) infusion, showing the feasibility
and tolerability of the addition of ATIR(TM) in combination with a mismatched
Following scientific advice from the EMEA Kiadis Pharma is preparing to
initiate a multi center multinational pivotal study starting recruitment
early 2009. In this study the efficacy of ATIR(TM) will be investigated in
patients diagnosed with AML, ALL or MDS eligible for an allogeneic bone
marrow transplantation but for whom no matching donor is available.
"Bone marrow transplantations are often the only treatment option left
for end-stage blood cancer patients. But too many patients simply do not find
a suitable matched donor in time" says Dr. Denis-Claude Roy of the
Maisonneuve-Rosemont Hospital in Montreal, the principal investigator on the
study. "Our study shows a rapid immune reconstitution in transplanted
patients provided with ATIR(TM) treated immune cells from mismatched donors.
Without ATIR(TM) treatment this would not be possible because of the high
risk of acute Graft versus Host Disease with mismatched donor immune cells.
This is obviously a very hopeful development for a large patient group."
Dr. Manja Bouman, CEO of Kiadis Pharma, says "The results of this
clinical trial are very encouraging and it is another important milestone in
the development of ATIR(TM) as a novel approach which may enable a safe and
potentially life-saving mismatched bone marrow transplantation as a treatment
option for end-stage blood cancer patients."
For the complete press release please go to: http://www.kiadis.com/news
English release is provided by Kiadis Pharma. Equivalent translations are
from a third party.
SOURCE Kiadis Pharma